The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2022
Filed:
Nov. 26, 2019
Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
Applicant:
Oregon Health & Science University, Portland, OR (US);
Inventors:
Louis Picker, Portland, OR (US);
Scott Hansen, Portland, OR (US);
Klaus Frueh, Portland, OR (US);
Daniel Malouli, Hillsboro, OR (US);
Jay Nelson, Portland, OR (US);
Jonah Sacha, Beaverton, OR (US);
Meaghan Hancock, Aloha, OR (US);
Assignee:
OREGON HEALTH & SCIENCE UNIVERSITY, Portland, OR (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); C12N 7/04 (2006.01); C12N 15/86 (2006.01); C12N 15/113 (2010.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01);
U.S. Cl.
CPC ...
A61K 45/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 7/045 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); A61K 2039/572 (2013.01); C12N 2310/141 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16143 (2013.01); C12N 2710/16171 (2013.01); C12N 2740/15034 (2013.01); Y02A 50/30 (2018.01);
Abstract
CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.